Drug information of Ferumoxytol


Drug group:

Ferumoxytol is an intravenously administered iron preparation for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD).

It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution.

Mechanism of effect

Iron-carbohydrate complex released within macrophage vesicles; either enters intracellular iron storage (eg, ferritin) or transferred to plasma transferrin for transport to erythroid precursor cells for hemoglobin incorporation


Iron is a part of myoglobin and several heme-enzymes, including the cytochromes, catalase, and peroxidase. Iron is an essential component of the metalloflavoprotein enzymes and the mitochondrial enzyme alpha-glycerophosphate oxidase. In addition, iron is a cofactor for enzymes such as aconitase and tryptophan pyrrolase. Iron deficiency cause anemia and decreased oxygen delivery. This also reduces the metabolism of muscle and decreases mitochondrial activity. Iron deficiency may also cause defects in both learning or thermoregulation. Therefore, iron is important to several metabolic functions in addition to erythropoiesis.


Peak plasma concentration: 206 mcg/mL

Peak plasma time: 0.32 hr

Vd: 3.16 L (two 510 mg-dose administered IV within 24 hr)

Half-life: 15 hr

Clearance: 3.16 L

Drug indications

Iron-deficiency anemia (IDA)



Iron Deficiency Anemia

510 mg IV infused over 15 min once, followed by a second dose 3-8 days later


<18 years: Safety and efficacy not established

Drug contraindications

Known hypersensitivity to ferumoxytol or any of its components History of allergic reaction to any intravenous iron product




Elderly patients (>65 years) or patients with multiple comorbidities who experience a serious hypersensitivity reaction due to ferumoxytol may have more severe outcomes

Risk of anaphylaxis increases in patients with multiple drug allergies

Clinically significant hypotension may occur; in a clinical study with ferumoxytol in patients with IDA, regardless of etiology, moderate hypotension was reported in 0.2% (2/997) of subjects

Excessive therapy with IV iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis; monitor the hematologic response during IV iron therapy; do not administer ferumoxytol to patients with iron overload; within 24 hr following administration, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring iron in the ferumoxytol

Can alter magnetic resonance imaging (MRI) studies

Black Box Warnings

Serious hypersensitivity/ anaphylaxis reactions

  • Fatal and serious hypersensitivity reactions including anaphylaxis have occurred
  • Initial symptoms may include hypotension, syncope, unresponsiveness, and cardiac/cardiorespiratory arrest
  • Only administer as IV infusion over at least 15 minutes when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions
  • Observe for signs or symptoms of hypersensitivity reactions during and for at least 30 minutes following infusion, including monitoring of blood pressure and pulse during and after administration
  • Hypersensitivity reactions have occurred in patients in whom a previous dose was tolerated

Points of recommendation

  • Tell all of your health care providers that you take ferumoxytol. This includes your doctors, nurses, pharmacists, and dentists.
  • This medicine may affect an MRI for up to 3 months after the last dose. This medicine may also affect certain tests for iron in the blood. Be sure your doctor and lab workers know you have received ferumoxytol.
  • Have blood work checked as you have been told by the doctor. Talk with the doctor.
  • Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using ferumoxytol while you are pregnant.
  • Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.

Ask a Pharmacist

User's questions
    No comments yet.